
Global SARS-CoV-2 IgG (RBD) ELISA Industry Growth and Trends Forecast to 2031
Description
Summary
According to APO Research, The global SARS-CoV-2 IgG (RBD) ELISA market was estimated at US$ million in 2025 and is projected to reach a revised size of US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2026-2031.
North American market for SARS-CoV-2 IgG (RBD) ELISA is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.
Asia-Pacific market for SARS-CoV-2 IgG (RBD) ELISA is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.
Europe market for SARS-CoV-2 IgG (RBD) ELISA is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.
The major global companies of SARS-CoV-2 IgG (RBD) ELISA include ALPCO, BD Biosciences, BioMérieux, Bio-Rad Laboratories, Enzo Life Sciences, LG, LOEWE Biochemica, Ortho Clinical Diagnostics and R&D Systems, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for SARS-CoV-2 IgG (RBD) ELISA, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding SARS-CoV-2 IgG (RBD) ELISA.
The SARS-CoV-2 IgG (RBD) ELISA market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global SARS-CoV-2 IgG (RBD) ELISA market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, gross margin by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
SARS-CoV-2 IgG (RBD) ELISA Segment by Company
ALPCO
BD Biosciences
BioMérieux
Bio-Rad Laboratories
Enzo Life Sciences
LG
LOEWE Biochemica
Ortho Clinical Diagnostics
R&D Systems
Shenzhen YHLO Biotech
ZEUS Scientific
Thermo Fisher Scientific
SARS-CoV-2 IgG (RBD) ELISA Segment by Type
ELISA Sets
ELISA Kits
SARS-CoV-2 IgG (RBD) ELISA Segment by Application
Hospital
Clinic
Disease control and prevention system
SARS-CoV-2 IgG (RBD) ELISA Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global SARS-CoV-2 IgG (RBD) ELISA market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of SARS-CoV-2 IgG (RBD) ELISA and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of SARS-CoV-2 IgG (RBD) ELISA.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2020-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of SARS-CoV-2 IgG (RBD) ELISA companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
According to APO Research, The global SARS-CoV-2 IgG (RBD) ELISA market was estimated at US$ million in 2025 and is projected to reach a revised size of US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2026-2031.
North American market for SARS-CoV-2 IgG (RBD) ELISA is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.
Asia-Pacific market for SARS-CoV-2 IgG (RBD) ELISA is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.
Europe market for SARS-CoV-2 IgG (RBD) ELISA is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.
The major global companies of SARS-CoV-2 IgG (RBD) ELISA include ALPCO, BD Biosciences, BioMérieux, Bio-Rad Laboratories, Enzo Life Sciences, LG, LOEWE Biochemica, Ortho Clinical Diagnostics and R&D Systems, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for SARS-CoV-2 IgG (RBD) ELISA, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding SARS-CoV-2 IgG (RBD) ELISA.
The SARS-CoV-2 IgG (RBD) ELISA market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global SARS-CoV-2 IgG (RBD) ELISA market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, gross margin by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
SARS-CoV-2 IgG (RBD) ELISA Segment by Company
ALPCO
BD Biosciences
BioMérieux
Bio-Rad Laboratories
Enzo Life Sciences
LG
LOEWE Biochemica
Ortho Clinical Diagnostics
R&D Systems
Shenzhen YHLO Biotech
ZEUS Scientific
Thermo Fisher Scientific
SARS-CoV-2 IgG (RBD) ELISA Segment by Type
ELISA Sets
ELISA Kits
SARS-CoV-2 IgG (RBD) ELISA Segment by Application
Hospital
Clinic
Disease control and prevention system
SARS-CoV-2 IgG (RBD) ELISA Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global SARS-CoV-2 IgG (RBD) ELISA market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of SARS-CoV-2 IgG (RBD) ELISA and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of SARS-CoV-2 IgG (RBD) ELISA.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2020-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of SARS-CoV-2 IgG (RBD) ELISA companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
Table of Contents
103 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global SARS-CoV-2 IgG (RBD) ELISA Market Size Overview by Region 2020 VS 2024 VS 2031
- 1.4 Global SARS-CoV-2 IgG (RBD) ELISA Market Size by Region (2020-2031)
- 1.4.1 Global SARS-CoV-2 IgG (RBD) ELISA Market Size by Region (2020-2025)
- 1.4.2 Global SARS-CoV-2 IgG (RBD) ELISA Market Size by Region (2026-2031)
- 1.5 Key Regions SARS-CoV-2 IgG (RBD) ELISA Market Size (2020-2031)
- 1.5.1 North America SARS-CoV-2 IgG (RBD) ELISA Market Size Growth Rate (2020-2031)
- 1.5.2 Europe SARS-CoV-2 IgG (RBD) ELISA Market Size Growth Rate (2020-2031)
- 1.5.3 Asia-Pacific SARS-CoV-2 IgG (RBD) ELISA Market Size Growth Rate (2020-2031)
- 1.5.4 South America SARS-CoV-2 IgG (RBD) ELISA Market Size Growth Rate (2020-2031)
- 1.5.5 Middle East & Africa SARS-CoV-2 IgG (RBD) ELISA Market Size Growth Rate (2020-2031)
- 2 SARS-CoV-2 IgG (RBD) ELISA Market by Type
- 2.1 Type Introduction
- 2.1.1 ELISA Sets
- 2.1.2 ELISA Kits
- 2.2 Global SARS-CoV-2 IgG (RBD) ELISA Market Size by Type
- 2.2.1 Global SARS-CoV-2 IgG (RBD) ELISA Market Size Overview by Type (2020-2031)
- 2.2.2 Global SARS-CoV-2 IgG (RBD) ELISA Historic Market Size Review by Type (2020-2025)
- 2.2.3 Global SARS-CoV-2 IgG (RBD) ELISA Market Size Forecasted by Type (2026-2031)
- 2.3 Global SARS-CoV-2 IgG (RBD) ELISA Market Size by Regions
- 2.3.1 North America SARS-CoV-2 IgG (RBD) ELISA Market Size Breakdown by Type (2020-2025)
- 2.3.2 Europe SARS-CoV-2 IgG (RBD) ELISA Market Size Breakdown by Type (2020-2025)
- 2.3.3 Asia-Pacific SARS-CoV-2 IgG (RBD) ELISA Market Size Breakdown by Type (2020-2025)
- 2.3.4 South America SARS-CoV-2 IgG (RBD) ELISA Market Size Breakdown by Type (2020-2025)
- 2.3.5 Middle East and Africa SARS-CoV-2 IgG (RBD) ELISA Market Size Breakdown by Type (2020-2025)
- 3 SARS-CoV-2 IgG (RBD) ELISA Market by Application
- 3.1 Type Introduction
- 3.1.1 Hospital
- 3.1.2 Clinic
- 3.1.3 Disease control and prevention system
- 3.2 Global SARS-CoV-2 IgG (RBD) ELISA Market Size by Application
- 3.2.1 Global SARS-CoV-2 IgG (RBD) ELISA Market Size Overview by Application (2020-2031)
- 3.2.2 Global SARS-CoV-2 IgG (RBD) ELISA Historic Market Size Review by Application (2020-2025)
- 3.2.3 Global SARS-CoV-2 IgG (RBD) ELISA Market Size Forecasted by Application (2026-2031)
- 3.3 Global SARS-CoV-2 IgG (RBD) ELISA Market Size by Regions
- 3.3.1 North America SARS-CoV-2 IgG (RBD) ELISA Market Size Breakdown by Application (2020-2025)
- 3.3.2 Europe SARS-CoV-2 IgG (RBD) ELISA Market Size Breakdown by Application (2020-2025)
- 3.3.3 Asia-Pacific SARS-CoV-2 IgG (RBD) ELISA Market Size Breakdown by Application (2020-2025)
- 3.3.4 South America SARS-CoV-2 IgG (RBD) ELISA Market Size Breakdown by Application (2020-2025)
- 3.3.5 Middle East and Africa SARS-CoV-2 IgG (RBD) ELISA Market Size Breakdown by Application (2020-2025)
- 4 Global Market Dynamics
- 4.1 SARS-CoV-2 IgG (RBD) ELISA Industry Trends
- 4.2 SARS-CoV-2 IgG (RBD) ELISA Industry Drivers
- 4.3 SARS-CoV-2 IgG (RBD) ELISA Industry Opportunities and Challenges
- 4.4 SARS-CoV-2 IgG (RBD) ELISA Industry Restraints
- 5 Competitive Insights by Company
- 5.1 Global Top Players by SARS-CoV-2 IgG (RBD) ELISA Revenue (2020-2025)
- 5.2 Global SARS-CoV-2 IgG (RBD) ELISA Industry Company Ranking, 2023 VS 2024 VS 2025
- 5.3 Global SARS-CoV-2 IgG (RBD) ELISA Key Company Headquarters & Area Served
- 5.4 Global SARS-CoV-2 IgG (RBD) ELISA Company, Product Type & Application
- 5.5 Global SARS-CoV-2 IgG (RBD) ELISA Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global SARS-CoV-2 IgG (RBD) ELISA Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 SARS-CoV-2 IgG (RBD) ELISA Players Market Share by Revenue in 2024
- 5.6.3 2024 SARS-CoV-2 IgG (RBD) ELISA Tier 1, Tier 2, and Tier 3
- 6 Company Profiles
- 6.1 ALPCO
- 6.1.1 ALPCO Comapny Information
- 6.1.2 ALPCO Business Overview
- 6.1.3 ALPCO SARS-CoV-2 IgG (RBD) ELISA Revenue, Global Share and Gross Margin (2020-2025)
- 6.1.4 ALPCO SARS-CoV-2 IgG (RBD) ELISA Product Portfolio
- 6.1.5 ALPCO Recent Developments
- 6.2 BD Biosciences
- 6.2.1 BD Biosciences Comapny Information
- 6.2.2 BD Biosciences Business Overview
- 6.2.3 BD Biosciences SARS-CoV-2 IgG (RBD) ELISA Revenue, Global Share and Gross Margin (2020-2025)
- 6.2.4 BD Biosciences SARS-CoV-2 IgG (RBD) ELISA Product Portfolio
- 6.2.5 BD Biosciences Recent Developments
- 6.3 BioMérieux
- 6.3.1 BioMérieux Comapny Information
- 6.3.2 BioMérieux Business Overview
- 6.3.3 BioMérieux SARS-CoV-2 IgG (RBD) ELISA Revenue, Global Share and Gross Margin (2020-2025)
- 6.3.4 BioMérieux SARS-CoV-2 IgG (RBD) ELISA Product Portfolio
- 6.3.5 BioMérieux Recent Developments
- 6.4 Bio-Rad Laboratories
- 6.4.1 Bio-Rad Laboratories Comapny Information
- 6.4.2 Bio-Rad Laboratories Business Overview
- 6.4.3 Bio-Rad Laboratories SARS-CoV-2 IgG (RBD) ELISA Revenue, Global Share and Gross Margin (2020-2025)
- 6.4.4 Bio-Rad Laboratories SARS-CoV-2 IgG (RBD) ELISA Product Portfolio
- 6.4.5 Bio-Rad Laboratories Recent Developments
- 6.5 Enzo Life Sciences
- 6.5.1 Enzo Life Sciences Comapny Information
- 6.5.2 Enzo Life Sciences Business Overview
- 6.5.3 Enzo Life Sciences SARS-CoV-2 IgG (RBD) ELISA Revenue, Global Share and Gross Margin (2020-2025)
- 6.5.4 Enzo Life Sciences SARS-CoV-2 IgG (RBD) ELISA Product Portfolio
- 6.5.5 Enzo Life Sciences Recent Developments
- 6.6 LG
- 6.6.1 LG Comapny Information
- 6.6.2 LG Business Overview
- 6.6.3 LG SARS-CoV-2 IgG (RBD) ELISA Revenue, Global Share and Gross Margin (2020-2025)
- 6.6.4 LG SARS-CoV-2 IgG (RBD) ELISA Product Portfolio
- 6.6.5 LG Recent Developments
- 6.7 LOEWE Biochemica
- 6.7.1 LOEWE Biochemica Comapny Information
- 6.7.2 LOEWE Biochemica Business Overview
- 6.7.3 LOEWE Biochemica SARS-CoV-2 IgG (RBD) ELISA Revenue, Global Share and Gross Margin (2020-2025)
- 6.7.4 LOEWE Biochemica SARS-CoV-2 IgG (RBD) ELISA Product Portfolio
- 6.7.5 LOEWE Biochemica Recent Developments
- 6.8 Ortho Clinical Diagnostics
- 6.8.1 Ortho Clinical Diagnostics Comapny Information
- 6.8.2 Ortho Clinical Diagnostics Business Overview
- 6.8.3 Ortho Clinical Diagnostics SARS-CoV-2 IgG (RBD) ELISA Revenue, Global Share and Gross Margin (2020-2025)
- 6.8.4 Ortho Clinical Diagnostics SARS-CoV-2 IgG (RBD) ELISA Product Portfolio
- 6.8.5 Ortho Clinical Diagnostics Recent Developments
- 6.9 R&D Systems
- 6.9.1 R&D Systems Comapny Information
- 6.9.2 R&D Systems Business Overview
- 6.9.3 R&D Systems SARS-CoV-2 IgG (RBD) ELISA Revenue, Global Share and Gross Margin (2020-2025)
- 6.9.4 R&D Systems SARS-CoV-2 IgG (RBD) ELISA Product Portfolio
- 6.9.5 R&D Systems Recent Developments
- 6.10 Shenzhen YHLO Biotech
- 6.10.1 Shenzhen YHLO Biotech Comapny Information
- 6.10.2 Shenzhen YHLO Biotech Business Overview
- 6.10.3 Shenzhen YHLO Biotech SARS-CoV-2 IgG (RBD) ELISA Revenue, Global Share and Gross Margin (2020-2025)
- 6.10.4 Shenzhen YHLO Biotech SARS-CoV-2 IgG (RBD) ELISA Product Portfolio
- 6.10.5 Shenzhen YHLO Biotech Recent Developments
- 6.11 ZEUS Scientific
- 6.11.1 ZEUS Scientific Comapny Information
- 6.11.2 ZEUS Scientific Business Overview
- 6.11.3 ZEUS Scientific SARS-CoV-2 IgG (RBD) ELISA Revenue, Global Share and Gross Margin (2020-2025)
- 6.11.4 ZEUS Scientific SARS-CoV-2 IgG (RBD) ELISA Product Portfolio
- 6.11.5 ZEUS Scientific Recent Developments
- 6.12 Thermo Fisher Scientific
- 6.12.1 Thermo Fisher Scientific Comapny Information
- 6.12.2 Thermo Fisher Scientific Business Overview
- 6.12.3 Thermo Fisher Scientific SARS-CoV-2 IgG (RBD) ELISA Revenue, Global Share and Gross Margin (2020-2025)
- 6.12.4 Thermo Fisher Scientific SARS-CoV-2 IgG (RBD) ELISA Product Portfolio
- 6.12.5 Thermo Fisher Scientific Recent Developments
- 7 North America
- 7.1 North America SARS-CoV-2 IgG (RBD) ELISA Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 7.2 North America SARS-CoV-2 IgG (RBD) ELISA Market Size by Country (2020-2025)
- 7.3 North America SARS-CoV-2 IgG (RBD) ELISA Market Size Forecast by Country (2026-2031)
- 8 Europe
- 8.1 Europe SARS-CoV-2 IgG (RBD) ELISA Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 8.2 Europe SARS-CoV-2 IgG (RBD) ELISA Market Size by Country (2020-2025)
- 8.3 Europe SARS-CoV-2 IgG (RBD) ELISA Market Size Forecast by Country (2026-2031)
- 9 Asia-Pacific
- 9.1 Asia-Pacific SARS-CoV-2 IgG (RBD) ELISA Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 9.2 Asia-Pacific SARS-CoV-2 IgG (RBD) ELISA Market Size by Country (2020-2025)
- 9.3 Asia-Pacific SARS-CoV-2 IgG (RBD) ELISA Market Size Forecast by Country (2026-2031)
- 10 South America
- 10.1 South America SARS-CoV-2 IgG (RBD) ELISA Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 10.2 South America SARS-CoV-2 IgG (RBD) ELISA Market Size by Country (2020-2025)
- 10.3 South America SARS-CoV-2 IgG (RBD) ELISA Market Size Forecast by Country (2026-2031)
- 11 Middle East & Africa
- 11.1 Middle East & Africa SARS-CoV-2 IgG (RBD) ELISA Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 11.2 Middle East & Africa SARS-CoV-2 IgG (RBD) ELISA Market Size by Country (2020-2025)
- 11.3 Middle East & Africa SARS-CoV-2 IgG (RBD) ELISA Market Size Forecast by Country (2026-2031)
- 12 Concluding Insights
- 13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.